Douglas J. Williamson - Feb 10, 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
Executive VP, Research & Dev
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Feb 10, 2023
Transactions value $
$0
Form type
4
Date filed
2/13/2023, 05:45 PM
Previous filing
Feb 13, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Non-Qualified Stock Option (Right to Buy) Award $0 +237K $0.00 237K Feb 10, 2023 Common Stock 237K $18.97 Direct F1
transaction ACAD Restricted Stock Units Award $0 +50.7K $0.00 50.7K Feb 10, 2023 Common Stock 50.7K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option vest on the first anniversary of February 10, 2023, with the balance vesting in 36 equal monthly installments thereafter, such that the shares subject to the option will be fully vested on the fourth anniversary of such date.
F2 Each restricted stock unit is subject to the 2023 Inducement Plan and represents a contingent right to receive one share of Acadia common stock.
F3 50% of the shares subject to the restricted stock units vest on the second anniversary of February 10, 2023, with the balance vesting in two equal annual installments thereafter, such that the shares subject to the restricted stock units will be fully vested on the fourth anniversary of such date.